
other industrialized nations. In 2001, the U.S. Medicare program spent an estimated >$4.3 billion on PAD-related treatment.7 PAD-related treatment accounted for w13% of all
Medicare Part A and B expenditures for patients undergoing
treatment for PAD and for 2.3% of total Medicare Part A and
B expenditures during that year. These Medicare costs have
continued to increase markedly. Analysis of data from the
Reduction of